



Dr. Helen McShane
Oxford University

Dr. Helen McShane trained in medicine at Guy's Hospital, London. After junior hospital jobs in London, Brighton and Oxford, she was awarded an MRC Clinical Training Fellowship in 1997. She undertook a PhD with Professor Adrian Hill in Oxford investigating prime-boost immunisation strategies in the murine model of tuberculosis. In 2001, she was awarded a Wellcome Trust Clinician Scientist Fellowship, to evaluate these promising immunisation strategies and candidate vaccines in a series of Phase I clinical trials. She became a consultant in HIV and genito-urinary medicine in 2003 and in June 2005 was awarded a Wellcome Trust Senior Clinical Fellowship. In 2008, she was appointed a Fellow of the Royal College of Physicians, in London, then a Reader in Vaccinology by the University of Oxford.

She now leads the TB vaccine programme at Oxford University and is working on a BCG challenge model. MVA85A, the original new TB vaccine developed at Oxford, was the first new TB vaccine to enter into clinical trials in 2002. MVA85A is currently in clinical trials in the UK, The Gambia, Senegal and South Africa and is one of the world's leading new TB vaccines. An infant Phase IIb efficacy trial with this vaccine in South Africa commenced in April 2009 in collaboration with the South African TB Vaccine Initiative and Aeras Global TB Foundation.